Skip to main content

Table 2 Univariate and multivariate associations of CD44/CD24 expression and other risk factors with gastric cancer recurrence

From: CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis

Characteristics Recurrence rate Univariate  P -value Model 1†  P -value Model 2‡  P -value
   OR (95%CI)   aOR (95%CI)   aOR (95%CI)  
CD44 expression        
CD44- 50.0% (10/20) 1.00 (reference) -- 1.00 (reference) --   
CD44+ 50.0% (10/20) 1.00 (0.29-3.45) 1.000 0.66 (0.10-4.26) 0.658   
CD24 expression        
CD24- 43.5% (10/23) 1.00 (reference) -- 1.00 (reference) --   
CD24+ 58.8% (10/17) 1.86 (0.52-6.61) 0.339 0.09 (0.01-1.35) 0.081   
CD44 / CD24 expression        
CD44-/CD24- 38.5% (5/13) 1.00 (reference) --    1.00 (reference) --
CD44-/CD24+ 71.4% (5/7) 4.00 (0.55-29.10) 0.171    0.60 (0.03-10.67) 0.731
CD44+/CD24- 50.0% (5/10) 1.60 (0.30-8.49) 0.581    1.61 (0.15-17.36) 0.695
CD44+/CD24+ 50.0% (5/10) 1.60 (0.30-8.49) 0.581    0.06 (0.002-2.31) 0.131
Gender        
Male 63.2% (12/19) 2.79 (0.77-10.04) 0.117 39.64 (1.85-848.44) 0.019* 21.59 (1.24-377.26) 0.035*
Female 38.1% (8/21) 1.00 (reference) -- 1.00 (reference) -- 1.00 (reference) --
Age (years)        
≤65 37.5% (6/16) 1.00 (reference) -- 1.00 (reference) -- 1.00 (reference) --
>65 58.3% (14/24) 2.33 (0.64-8.54) 0.201 7.77 (0.89-67.99) 0.064 4.07 (0.49-34.16) 0.196
Histology        
Moderately differentiated (intestinal type) 60.0% (9/15) 1.91 (0.52-7.01) 0.330     
Poorly differentiated (diffuse type) 44.0% (11/25) 1.00 (reference) --     
Tumor location        
Upper third + Middle third 37.5% (6/16) 1.00 (reference) --     
Lower third 58.3% (14/24) 2.33 (0.64-8.54) 0.201     
TNM Stage        
I-IIa 21.1% (4/19) 1.00 (reference) -- 1.00 (reference) -- 1.00 (reference) --
III-IV 76.2% (16/21) 12.0 (2.70-53.3) 0.001* 9.63 (1.05-88.76) 0.046* 41.01 (3.62-464.91) 0.003*
Lymph node metastasis        
No 15.4% (2/13) 1.00 (reference) -- 1.00 (reference) --   
Yes 66.7% (18/27) 11.0 (2.00-60.5) 0.006* 20.92 (1.20-365.55) 0.037*   
Number of lymph node metastasis        
0 15.4% (2/13) 1.00 (reference) --     
1-4 s 60.0% (9/15) 8.25 (1.33-51.2) 0.024*     
≥5 75.0% (9/12) 16.5 (2.25-121.2) 0.006*     
  1. † In multivariate Model 1, CD44 and CD24 expression were considered as two variables.
  2. ‡ In multivariate Model 2, CD44 and CD24 expression were combined as one variable to show different combinations.
  3. a Two control patients with TNM Stage 0 were grouped into Stage I-II.
  4. Note: OR, odds ratio; aOR, adjusted odds ratio.
  5. *P<0.05.